Gunnar Birgegård

8.9k total citations · 3 hit papers
121 papers, 4.8k citations indexed

About

Gunnar Birgegård is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Gunnar Birgegård has authored 121 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hematology, 68 papers in Genetics and 23 papers in Molecular Biology. Recurrent topics in Gunnar Birgegård's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (40 papers), Erythropoietin and Anemia Treatment (35 papers) and Iron Metabolism and Disorders (35 papers). Gunnar Birgegård is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (40 papers), Erythropoietin and Anemia Treatment (35 papers) and Iron Metabolism and Disorders (35 papers). Gunnar Birgegård collaborates with scholars based in Sweden, Germany and Italy. Gunnar Birgegård's co-authors include Leif Wide, Heinz Ludwig, Pere Gascón, Tiziano Barbui, Giovanni Barosi, Carsten Bokemeyer, Maciej Krzakowski, M. Schneider, Dirk Schrijvers and Alessandro M. Vannucchi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gunnar Birgegård

119 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

2004 678 citations Heinz Ludwig, Gunnar Birgegård et al. profile →
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

2007 604 citations Ayalew Tefferi, Jüergen Thiele et al. Blood profile →
European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

2014 421 citations Gunnar Birgegård et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gunnar Birgegård Sweden	33	3.1k	2.6k	1.2k	859	557	121	4.8k
Miguel R. Abboud Lebanon	36	4.3k 1.4×	4.7k 1.8×	434 0.3×	368 0.4×	497 0.9×	188	7.2k
Mehran Karimi Iran	37	3.4k 1.1×	3.1k 1.2×	492 0.4×	166 0.2×	158 0.3×	364	5.7k
Christian Breymann Switzerland	35	1.8k 0.6×	1.6k 0.6×	292 0.2×	136 0.2×	232 0.4×	96	3.7k
Amy D. Shapiro United States	44	5.6k 1.8×	1.4k 0.5×	987 0.8×	88 0.1×	228 0.4×	230	6.8k
P.M. Mannucci Italy	37	3.1k 1.0×	643 0.2×	383 0.3×	215 0.3×	90 0.2×	129	4.7k
David Gómez‐Almaguer Mexico	29	1.9k 0.6×	700 0.3×	327 0.3×	178 0.2×	579 1.0×	335	3.0k
Kathelijn Fischer Netherlands	52	7.5k 2.4×	2.2k 0.8×	1.0k 0.8×	234 0.3×	218 0.4×	287	9.1k
Lakshmanan Krishnamurti United States	33	2.3k 0.7×	2.9k 1.1×	633 0.5×	60 0.1×	132 0.2×	192	4.2k
Jean‐Christophe Gris France	40	2.5k 0.8×	316 0.1×	344 0.3×	1.3k 1.5×	110 0.2×	288	5.8k
Fausto R. Loberiza United States	41	2.8k 0.9×	1.4k 0.5×	505 0.4×	128 0.1×	1.8k 3.2×	136	6.2k

Countries citing papers authored by Gunnar Birgegård

Since Specialization

Citations

This map shows the geographic impact of Gunnar Birgegård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gunnar Birgegård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gunnar Birgegård more than expected).

Fields of papers citing papers by Gunnar Birgegård

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gunnar Birgegård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gunnar Birgegård. The network helps show where Gunnar Birgegård may publish in the future.

Co-authorship network of co-authors of Gunnar Birgegård

This figure shows the co-authorship network connecting the top 25 collaborators of Gunnar Birgegård. A scholar is included among the top collaborators of Gunnar Birgegård based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gunnar Birgegård. Gunnar Birgegård is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Birgegård, Gunnar, Yasin Folkvaljon, Hans Garmo, et al.. (2016). Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy. Haematologica. 101. 96–96. 1 indexed citations

Birgegård, Gunnar, Carlos Besses, Martin Grießhammer, et al.. (2015). RISK FACTORS FOR THROMBOHEMORRHAGIC AND TRANSFORMATION EVENTS IN 3649 HIGH-RISK PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA : RESULTS FROM THE PROSPECTIVE LONG-TERM OBSERVATIONAL EXELS STUDY. Haematologica. 100(3). 160–161. 1 indexed citations

Birgegård, Gunnar. (2015). Erythropoiesis and Inflammation. Contributions to nephrology. 76. 330–341. 1 indexed citations

Hedenus, Michael, et al.. (2014). Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Medical Oncology. 31(12). 302–302. 31 indexed citations

Birgegård, Gunnar. (2014). Does anything work for anaemia in myelofibrosis?. Best Practice & Research Clinical Haematology. 27(2). 175–185. 10 indexed citations

Öhrn, Kerstin, et al.. (2012). Five-year follow-up of survival and relapse in patients who received cryotherapy during high-dose chemotherapy for stem cell transplantation shows no safety concerns. European Journal of Cancer Care. 21(6). 822–828. 12 indexed citations

Björkholm, Magnus, Åsa Rangert Derolf, Malin Hultcrantz, et al.. (2011). Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology. 29(17). 2410–2415. 174 indexed citations

Nilsson‐Ehle, Herman, Gunnar Birgegård, Jan Samuelsson, et al.. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. European Journal Of Haematology. 87(3). 244–252. 49 indexed citations

Barosi, Giovanni, Gunnar Birgegård, Guido Finazzi, et al.. (2009). A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology. 148(6). 961–963. 119 indexed citations

10.

Hedenus, Michael & Gunnar Birgegård. (2008). The role of iron supplementation during epoietin treatment for cancer-related anemia. Medical Oncology. 26(1). 105–115. 18 indexed citations

11.

Birgegård, Gunnar. (2008). Long-term management of thrombocytosis in essential thrombocythaemia. Annals of Hematology. 88(1). 1–10. 15 indexed citations

12.

Tefferi, Ayalew, Jüergen Thiele, Attilio Orazi, et al.. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110(4). 1092–1097. 604 indexed citations breakdown →

13.

Birgegård, Gunnar, et al.. (2007). Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy—a randomized controlled trial. Supportive Care in Cancer. 15(10). 1155–1161. 50 indexed citations

14.

Barosi, Giovanni, Carlos Besses, Gunnar Birgegård, et al.. (2006). A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 21(2). 277–280. 80 indexed citations

15.

Birgegård, Gunnar & Carsten Bokemeyer. (2005). New Guidelines on Anaemia Management in Patients with Cancer: How Do These Affect Clinical Practice?. Oncology. 69(Suppl. 2). 17–21. 5 indexed citations

16.

Rastad, Jonas, et al.. (1997). Biochemical indices of calcium homeostasis immediately after kidney transplantation. Endocrinology and Metabolism. 4. 41. 1 indexed citations

17.

Hellström-Lindberg, Eva, Gunnar Birgegård, Magnus Carlsson, et al.. (1993). A Combination of Granulocvte Colonv-Stimulating Factor and Erythiopoietin may Synergistically Improve the Anaemia in Patients with Myelodysplastic Syndromes. Leukemia & lymphoma. 11(3-4). 221–228. 52 indexed citations

18.

Andersen, P. B., Gunnar Birgegård, R. Nyman, & A. Hemmingsson. (1991). Magnetic resonance imaging in idiopathic hemochromatosis. European Journal Of Haematology. 47(3). 174–178. 19 indexed citations

19.

Hast, Robert, Thomas D. Miale, Jan Westin, et al.. (1983). Hereditary Ring Sideroblastic Anaemia and Christmas Disease in a Swedish Family. Scandinavian Journal of Haematology. 30(5). 444–450. 3 indexed citations

20.

Gebre‐Medhin, M & Gunnar Birgegård. (1981). Serum Ferritin in Ethiopian Mothers and their Newborn Infants. Relation to Iron Intake and Socio‐Economic Conditions. Scandinavian Journal of Haematology. 27(4). 247–252. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact